Jacob Gotlieb’s experience and success and a healthcare industry have earned him respect and title of titan for the healthcare industry. After successfully running such alternative investment firms in the industry like Merlin Biomed Group and Visium Capital the medical doctor and finance strategist is back with Altium Capital, which promises to disrupt the healthcare industry investment scenes one project at a time.
But why Altium Capital and what big projects has it recently undertaken?
Coming up with Altium Capital
In 1998, Jacob Gotlieb joined Merlin Biomed group, an alternative investment firm specializing in the healthcare industry and headed by Stuart Weisbrod, as a portfolio manager. The hedge fund would, however, wind down in 2005 and this prompted him to start his own health industry investment firm, Visium Capital. The new firm took off rapidly and reached a peak in 2016 with over $8 Billion in assets under management but would also be forced to wind down in early 2017.
Altium capital is, therefore, a continuation of Jacob Gotlieb’s longstanding vision of coming up with one of the most disruptive health investment platform for both his investors and industry players. It specializes in spotting and investing in technologically influenced brands and their equally innovative medical devices and treatment options.
While the company may still be in its developmental stages, this hasn’t stopped it from making bold investment moves including taking up a 5.6% percent stake in Oramed pharmaceuticals. The investment was inspired by Oramed’s development of an oral treatment alternative for diabetes patients that seeks to get them off the hook of the injectables.
Altium capital has also invested in the Dublin-based Amarin Corporation, a pharmaceutical that specializes in the development of drugs that improve cardiovascular health. In its most recent move, Altium, which currently shares office space with Weisbrod’s Iguana Healthcare Partners, has also invested in the replacement therapy inspired Oragenics. The funds are meant to help the pharmaceutical develop and commercialize their antibiotics that take on drug-resistant bacterial strains associated with several infectious diseases.